论文部分内容阅读
以克隆性免疫球蛋白重链（ＩｇＨ）基因重排为肿瘤细胞基因标志，在聚合酶链反应基础上结合应用ＤＮＡ单链构象多态性分析（ＰＣＲ－ＳＳＣＰ）技术对病人骨髓标本进行微小残存病变（ＭＲＤ）检测。３８例形态学检查正常的Ｂ细胞非何杰金淋巴瘤（Ｒ－ＮＨＬ）病人治疗前骨髓标本，ＭＲＤ检出率为６８．４％（２６／３８），骨髓ＭＲＤ阳性的Ｂ－ＮＨＬ病人生存期明显短于ＭＲＤ阴性病人（Ｐ＜０．０５）。２１例８细胞急性淋巴细胞白血病（Ｂ－ＡＬＬ）完全缓解期采集的骨髓标本，ＭＲＤ检出率为７１．４％（１５／２１）。骨髓中ＭＲＤ阴性的Ｒ－ＡＬＬ病人无病存活期明显长于ＭＲＤ持续阳性病人（Ｐ＜０．０５）。骨髓中ＭＲＤ检测可以协助估价Ｂ淋巴细胞恶性肿瘤病人预后、判断疗效及监测复发。
The clonal immunoglobulin heavy chain (IgH) gene rearrangement is used as the gene signature of tumor cells. The PCR-SSCP technique is applied to the microscopic remnants of patients’ bone marrow specimens based on polymerase chain reaction. MRD detection. 38 patients with normal B-cell non-Hodgkin’s lymphoma (R-NHL) who had normal morphological examination were treated with bone marrow specimens. The detection rate of MRD was 68.4% (26/38). B-NHL patients with bone marrow MRD positive survived. The period was significantly shorter than that of MRD-negative patients (P<0.05). Twenty-one bone marrow specimens collected from 8 patients with acute lymphoblastic leukemia (B-ALL) were completely resolved. The detection rate of MRD was 71.4% (15/21). The disease-free survival of MRD-negative R-ALL patients in bone marrow was significantly longer than that in MRD patients (P<0.05). Detection of MRD in the bone marrow can help evaluate the prognosis of patients with B-lymphocyte malignancy, judge the efficacy, and monitor recurrence.